Vernalis enters collaboration with Genentech

Vernalis enters collaboration with Genentech

Vernalis plc enters into drug discovery collaboration with Genentech

Vernalis plc (LSE: VER) announced today that it has entered into a drug discovery collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG: OTCQX: RHHBY) utilising Vernalis' fragment and structure-based drug discovery platform against an undisclosed target.

The financial terms of this collaboration were not disclosed.

Ian Garland, CEO of Vernalis, commented: "We are delighted that Genentech has selected Vernalis to work with it on this target. Their selection of Vernalis further endorses our market leading fragment and structure-based drug discovery platform and validates our strategy to substantially fund our research activities through collaborations. We look forward to building a close working relationship with Genentech and ultimately a successful collaboration."

James Sabry, Vice President of Genentech Partnering, said "Genentech constantly seeks collaborations like this one to develop therapies that offer the potential of advancing the standard of care and making a meaningful difference in the lives of patients. We are very pleased to enter into this agreement with Vernalis."

 

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.